The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000786392p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
19/05/2026
Date registered
Help: Date registered
1/07/2026
Date last updated
Help: Date last updated
1/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
1/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Injection of processed cells from a patient’s own fat into the spine for adults with chronic degenerative low back pain: effect on 12-month pain intensity
Scientific title
A randomised, double-blind, placebo-controlled study of intradiscal and facet joint administration of autologous stromal vascular fraction (E2Spine) versus placebo in adults with chronic degenerative low back pain, assessing change in low back pain intensity at 12 months
Additional trial identifiers [1] 317157 0
E2Spine001
Universal Trial Number (UTN)
Trial acronym
E2Spine-001
Related trial records

Health condition
Health condition(s) studied:
Chronic Lower Back Pain 341988 0
Condition category
Condition code
Musculoskeletal 338065 338065 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The intervention is a single administration of autologous stromal vascular fraction (SVF; E2Spine) prepared from the participant’s own adipose tissue. On Day 0, approximately 100–150 mL of adipose tissue is harvested by standardised tumescent mini-liposuction from a suitable donor site, such as the abdomen, flank, back, or thigh. The lipoaspirate is processed on-site under aseptic conditions using a standardised mechanical, non-enzymatic method based on StroMed ultrasonic cavitation to isolate SVF.
The prepared SVF is suspended in Plasma-Lyte and administered under fluoroscopic image guidance to the target lumbar functional spinal unit. Administration includes intradiscal injection into the index intervertebral disc, peri-radicular application adjacent to the symptomatic nerve root, and injection into the ipsilateral facet joint(s), as clinically indicated and within protocol-defined anatomical limits. Intradiscal delivery is performed slowly using a pressure-monitored syringe system, with continuous monitoring of injection resistance, intradiscal pressure, and participant symptoms. Injection is paused or discontinued if excessive resistance, marked pressure rise, vascular uptake, radicular symptoms, or significant discomfort occurs. The total injection period for each target site is expected to be brief and should not exceed approximately 5 minutes per site, excluding needle placement, confirmation, and any dwell period.
The target SVF dose is 40 × 106 viable nucleated cells for the index disc, 5 × 106 viable nucleated cells for the peri-radicular region at the index level, and 10 × 106 viable nucleated cells per ipsilateral facet joint, up to two facet joints. Approximate injection volumes are 0.8 mL intradiscally, 0.2 mL peri-radicularly, and 0.4 mL per facet joint, with a maximum total facet injection volume of 0.8 mL. Following intradiscal SVF delivery, the needle may be maintained in position for approximately 3–5 minutes to minimise reflux, and TISSEEL fibrin sealant is administered separately through the same tract as a protocol-defined adjunct to reduce egress from the annular puncture or fissure pathway.
Rescue medication is permitted according to protocol-defined criteria where pain is inadequately controlled or clinically significant pain flare occurs. Participants are encouraged to maintain stable background analgesic therapy where possible to minimise confounding. Short-term additional analgesia may be used when clinically necessary, and all rescue medication use, including medication type, dose, timing, duration, and indication, will be recorded. High-dose NSAIDs should be avoided during the first 72 hours after the procedure unless clinically required.
Intervention code [1] 334123 0
Treatment: Other
Intervention code [2] 334124 0
Treatment: Surgery
Description of the comparator or control
Plasma-Lyte placebo (vehicle control) administered via image-guided injections into the same anatomical targets (intradiscal and ipsilateral facet joints) and at matched volumes as the active treatment. The placebo contains no stromal vascular fraction (SVF) and is designed to mimic the injection procedure and maintain blinding; it has no independent intended pharmacological, immunological, or metabolic effect in this setting.
Control group
Placebo

Outcomes
Primary outcome [1] 345475 0
Change from baseline to Week 52 (Day 360) in 7-day average low back pain intensity, measured using the 11-point Numeric Rating Scale (NRS, 0–10), calculated as the mean of daily scores recorded over the 7 days preceding the Week 52 visit.
Timepoint [1] 345475 0
Change from baseline in 7-day average low back pain intensity (Numeric Rating Scale, 0–10), assessed at the following timepoints: Day 30 (±7 days) Day 90 (±14 days) Day 180 (±14 days) Day 270 (±14 days) Day 360 (Week 52; primary endpoint, ±30 days) The 7-day average is calculated from daily NRS scores recorded during the 7 days immediately preceding each assessment visit.
Secondary outcome [1] 461790 0
Functional disability
Timepoint [1] 461790 0
Day 30, Day 90, Day 180, Day 270, and Day 360 (Week 52) post injection
Secondary outcome [2] 461791 0
Health-related quality of life
Timepoint [2] 461791 0
EQ-5D-5L at Day 30, 90, 180, and 360 post injection SF-36 at Day 180 and Day 360 post injection
Secondary outcome [3] 461792 0
Patient global improvement
Timepoint [3] 461792 0
Day 30, 90, 180, and 360 post injection
Secondary outcome [4] 461793 0
clinically meaningful responder outcomes in pain and disability- composite
Timepoint [4] 461793 0
Week 52 post injection

Eligibility
Key inclusion criteria
Chronic degenerative low back pain of greater than 3 months and less than 5 years’ duration
Inadequate response to greater than 3 months of conservative therapy (e.g., medications, physiotherapy, etc.)
Baseline low back pain intensity of greater than 4 and less than 8 on the 0–10 Numeric Rating Scale (based on a 14-day screening average)
Oswestry Disability Index (ODI) greater than or equal to 40% at baseline
MRI evidence of lumbar degenerative pathology consistent with symptoms
Able to provide written informed consent and comply with study procedures
BMI greater than or equal to35 kg/m² and sufficient subcutaneous adipose tissue for harvest
Psychosocially and physically able to participate, with life expectancy >2 years
Minimum age
18 Years
Maximum age
49 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Spinal pathology/anatomy:

Prior lumbar spine surgery or discal intervention
Significant spinal deformity or instability
Severe spinal canal stenosis or clinically significant neurological compression
Lumbar disc herniation with radiculopathy
Multilevel or advanced degenerative disc disease outside protocol limits

Medical comorbidities:

Significant uncontrolled medical conditions (e.g. cardiovascular, renal, hepatic disease)
Diabetes mellitus, ischaemic heart disease, immunodeficiency
Active malignancy or malignancy within 5 years (with limited exceptions)
Clinically significant abnormal laboratory values
Positive serology for HIV, hepatitis B/C, or syphilis

Prior or concomitant treatments:

Prior intradiscal biologic therapy or recent corticosteroid injections
Participation in another clinical trial or use of investigational agents
Planned spinal surgery or intervention within the study period

Other exclusions:

Pregnancy or breastfeeding
BMI >35 kg/m² or insufficient adipose tissue for harvest
Severe psychiatric illness or pain catastrophising interfering with participation
Inability to comply with study procedures or provide informed consent

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
sealed opaque envelopes
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
computer-generated random sequence,
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Analysis populations:

Intent-to-Treat (ITT): all randomised participants, analysed by assigned treatment (primary efficacy population)
Per-Protocol (PP): participants without major protocol deviations (supportive analyses)
Safety population: all participants who undergo liposuction and/or receive study injection
Primary analysis:

Primary endpoint (change in 7-day average low back pain NRS at Week 52) analysed using a mixed model for repeated measures (MMRM)
Model includes treatment, timepoint, treatment×time interaction, and baseline NRS as fixed effects, with participant as a random effect
Results reported as least squares mean (LSM) change, between-group difference, confidence intervals, and p-value

Secondary analyses:

Continuous outcomes analysed using similar MMRM models
Binary/responder outcomes analysed using generalised mixed models (binomial distribution, log link)
Results presented as proportions, risk ratios, confidence intervals, and p-values

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment postcode(s) [1] 45854 0
2066 - Lane Cove North

Funding & Sponsors
Funding source category [1] 321741 0
Commercial sector/Industry
Name [1] 321741 0
E2SMed Pty Ltd
Country [1] 321741 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
E2SMed Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 324767 0
None
Name [1] 324767 0
Address [1] 324767 0
Country [1] 324767 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320283 0
Northern Sydney Local Health District Human Research Ethics Committee
Ethics committee address [1] 320283 0
Ethics committee country [1] 320283 0
Australia
Date submitted for ethics approval [1] 320283 0
24/04/2026
Approval date [1] 320283 0
Ethics approval number [1] 320283 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149974 0
Dr Wayne Thomas
Address 149974 0
E2SMed Pty Ltd; 448 Pacific Hwy, Lane Cove North, NSW 2066
Country 149974 0
Australia
Phone 149974 0
+61 42224802
Fax 149974 0
Email 149974 0
Contact person for public queries
Name 149975 0
Amelia Assareh
Address 149975 0
E2SMed Pty Ltd, 448 Pacific Hwy, Lane Cove North, NSW 2066
Country 149975 0
Australia
Phone 149975 0
+61 434507574
Fax 149975 0
Email 149975 0
Contact person for scientific queries
Name 149976 0
Wayne Thomas
Address 149976 0
E2SMed Pty Ltd, 448 Pacific Hwy, Lane Cove North, NSW 2066
Country 149976 0
Australia
Phone 149976 0
+61 42224802
Fax 149976 0
Email 149976 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.